MedTrace Logo

Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114

NCT05504876 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-12-21

No results posted yet for this study

Summary

This is a single center, open-label study to investigate whether HEC74647 and HEC110114 has an effect on the pharmacokinetic (PK) profile of midazolam（a cytochrome (CYP) 3A4 substrate）in healthy subjects

Conditions

  • Healthy Subjects

Interventions

DRUG

Midazolam Syrup

Administered Midazolam Syrup 5 mg orally once daily in fed state;

DRUG

HEC74647PA

Administered HEC74647PA 100 mg orally once daily in fed state;

DRUG

HEC110114

Administered HEC110114 600 mg orally once daily in fed state;

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhang Hong, Doctor · The First Hospital of Jilin University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2022-12-13
Completion
2022-12-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05504876 on ClinicalTrials.gov